Lupin and Gan & Lee enter exclusive licensing deal for novel GLP-1 receptor agonist

Lupin has bolstered its diabetes and obesity portfolios by securing an agreement for Bofanglutide, a GLP-1 receptor agonist developed by Gan & Lee Pharmaceuticals

Briefs: CuraTeQ Biologics, Sigachi Industries and Natural Capsules

CuraTeQ Biologics and BioFactura USA to terminate agreement mutually

WHO report reveals stark global inequities in genomic research

IRLAB launches Phase Ib Trial of IRL757 for Parkinson’s patients with Apathy

The multicenter study will enroll 75 patients across 16 sites in Germany, Bulgaria, Poland, and Spain

Nona Biosciences expands platform to accelerate early clinical trials

Nona aims to help global biopharmaceutical companies fast-track clinical trial initiation without compromising scientific rigor or quality standards

Teva moves within reach of investment grade as S&P upgrades credit rating & Moody’s positive

Dr Kaustav Talapatra named ASTRO’s International Ambassador from India

Sanofi to acquire Dynavax in $2.2 billion deal, bolstering adult vaccine portfolio

The move strengthens Sanofi’s presence in adult immunization by combining Dynavax’s innovative vaccines with Sanofi’s global scale and development capabilities

Niagen Bioscience secures full ownership of key NAD+ patents in major IP move

The portfolio includes foundational patents on the production, composition, and commercial use of NR

Asahi Kasei Pharma to move R&D hub to Shonan iPark in 2027

Shonan iPark was chosen for its globally connected life-science ecosystem, which unites pharmaceutical firms, next-generation medicine developers, AI and digital health innovators, venture capital, and academia